Clik here to view.
Keryx Pharma Is Overvalued By At Least 20%
Although we generally look for long plays in the biotechnology sector, certain macroeconomic factors can force us and other investors to look for short ideas. Currently, it’s growing more apparent that...
View ArticleDid Pozen Mislead Investors Concerning Its Recent FDA Rejection?
On Friday of last week, Pozen Inc.(POZN), received a CRL from the FDA, disallowing the New Drug Application (NDA) for its coordinated-delivery tablet combination of omeprazole (Prilosec) and aspirin....
View ArticleClik here to view.
Updated And Amended: Why Mannkind’s Afrezza Is No Blockbuster And Will Be...
Updated 6/22: Cleaned up thesis to include that we feel the stock price will tank hard even if Afrezza is approved. Background and Story of Afreza MannKind Corporation (MNKD) is a biopharmaceutical...
View ArticleClik here to view.
Looking Back at Chart From 2008 – Why Markets Will Crash Again
Looking Back at Chart From 2008 - Why Markets Will Crash - This may happen before the end of this month, or end of this year, possibly Q1, 2016, but it's almost certain that markets will crash due to...
View Article
